Clinical and Echocardiographic Characteristics After Six Months of Sacubitril Valsartan in Chagas Heart Disease.

Abstract

Chagas cardiomyopathy is the most prevalent non-ischemic cardiomyopathy\nin Latin America, with high morbidity and mortality even today.\nTreatment of these patients is based on the use of medications for heart\nfailure. This study evaluated a cohort of patients with Chagas heart\ndisease who used sacubitril valsartan at a referral hospital for the\ndisease in Brazil. After six months, there was a symptomatic improvement\nin these individuals assessed by the NYHA classification, with a 44.3%\nreduction in the absolute number of patients classified as III-IV in the\nperiod (p 0.035), but without changes in the parameters on the\nechocardiogram for reverse ventricular remodeling and still high\nmortality rate and hospitalization. These results emphasize the\nimportance of studying the use of sacubitril valsartan in chagas heart\ndisease to better describe its effectiveness taking into account the\npeculiarities of these individuals.